Clinical trials: Multiple Pregnancy
Urinary Bladder, Overactive
Study The Effects Of Different Doses Of UK-369,003 In Men With Overactive Bladder
This is a 12 week study in which different doses of UK-369,003 will be administered to patients with a diagnosis of overactive bladder.
- Trial name
- NCT00479505
- Testing
- UK-369,003
- Where
- 52 sites in Australia, Canada and 14 more
- Volunteers
- 275 people
- Sponsor
- Pfizer
Fallopian Tube Cancer, Ovarian Cancer
Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin and paclitaxel, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00091377
- Testing
- cisplatin, paclitaxel, phenoxodiol
- Where
- 2 sites in United States, Australia
- Volunteers
- 65 people
- Sponsor
- MEI Pharma, Inc.
Kidney Failure, Chronic
A Study of Obinutuzumab to Evaluate Safety and Tolerability in Hypersensitized Adult Participants With End Stage Renal Disease Awaiting Transplantation
This is a Phase Ib, open-label study of single and repeat doses of obinutuzumab administered as intravenous (IV) infusion in adults with end stage renal disease (ESRD).
- Trial name
- NCT02586051
- Testing
- Obinutuzumab, Intravenous Immunoglobulin
- Where
- 9 sites in United States
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
End-Stage Renal Disease
Decellularized Femoral Artery Allograft (Nexeon AVX) Prospective Registry
Post market registry to assess the safety and efficacy of a novel decellularized human femoral artery allograft (Nexeon AVX Decellularized Femoral Artery,
- Trial name
- NCT05880537
- Testing
- Nexeon Arterial Venous Allograft
- Where
- 4 sites in United States
- Volunteers
- 100 people
- Sponsor
- LifeNet Health
Gynecological Malignant Tumor, Solid Tumor
A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies
A phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics and efficacy of BL-B01D1 for injection in patients with multiple solid tumors, including recurrent or metastatic gynecological malignancies.
- Trial name
- NCT05803018
- Testing
- BL-B01D1
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Chronic Kidney Disease, Kidney Disease
Study for Subjects With Chronic Kidney Disease(CKD) Not Receiving Dialysis
The proposed study is designed to test a novel dosing paradigm that would facilitate the treatment of anemia in CKD patients not on dialysis.
- Trial name
- NCT00112008
- Testing
- De Novo Administration of Darbepoetin Alfa
- Volunteers
- 100 people
- Sponsor
- Amgen
End Stage Renal Disease (ESRD), Diabetes
Dianeal, Extraneal, Nutrineal (D-E-N) Versus Dianeal Only in Diabetic Continuous Ambulatory Peritoneal Dialysis (CAPD) Patients
Primary Objective: To demonstrate that use of glucose sparing prescriptions, Dianeal, Extraneal, Nutrineal (D-E-N) versus Dianeal only, in diabetic (Type 1 and Type 2) Continuous Ambulatory Peritoneal Dialysis (CAPD) patients…
- Conditions
- End Stage Renal Disease (ESRD), Diabetes, CAPD
- Trial name
- EDEN (NCT01219959)
- Testing
- Dianeal, Dianeal, Extraneal, Nutrineal
- Where
- 16 sites in Colombia
- Volunteers
- 71 people
- Sponsor
- Vantive Health LLC
Chronic Kidney Disease, Dialysis
A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia
This is a phase III multi-centre study in two periods: the first period is a phosphate binder and lipid lowering drugs washout for 8 weeks, the second period is a double-blind, randomised, parallel group, fixed dose, for 12 weeks.
- Conditions
- Chronic Kidney Disease, Dialysis, Hyperphosphatemia, Dyslipidemia
- Trial name
- NCT00542386
- Testing
- MCI-196
- Where
- 73 sites in Hungary, Italy and 6 more
- Volunteers
- 642 people
- Sponsor
- Tanabe Pharma Corporation
Endometriosis
A Study of HS-10518 in Healthy Female Participants
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HS-10518 in healthy adult premenopausal females in China.
- Trial name
- NCT06118827
- Testing
- HS-10518
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
NSCLC, SCLC
A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors
This is a Phase 1/2a, first-in-human, open-label study of JAB-8263, this study has two parts: solid tumor dose escalation and expansion study and hematology tumor dose escalation and expansion study.
- Conditions
- NSCLC, SCLC, CRPC, ESCC
- Trial name
- NCT04686682
- Testing
- JAB-8263
- Where
- China
- Volunteers
- 152 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
Down Syndrome, Edwards Syndrome
Clinical Performance of the MaterniT21 PLUS LDT in Multiple Gestation Pregnancies
This study will evaluate the clinical performance of massively parallel sequencing (MPS) using the MaterniT21 PLUS LDT in the detection of fetal aneuploidy in circulating cfDNA extracted from a maternal blood sample obtained from…
- Conditions
- Down Syndrome, Edwards Syndrome, Patau Syndrome, Turner Syndrome
- Trial name
- NCT02226315
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Sequenom, Inc.
Turner's Syndrome
An Open-Label, Multi-centre, Phase III Study of Local Tolerability of ZOMACTON 10MG
Children with growth failure due to inadequate secretion of growth hormone or growth retardation due to Turner's syndrome are individually dosed and treated for 12 weeks
- Trial name
- NCT00250250
- Testing
- ZOMACTON
- Where
- 6 sites in Czechia, France and 1 more
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Ferring Pharmaceuticals
Carcinoma, Renal Cell
Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma
In patients with renal cell cancer, most frequent methods of treatment include surgery, chemotherapy, hormonal therapy, and immunotherapy. Renal cell carcinoma is usually considered to be radioresistant and chemoresistant.
- Trial name
- NCT00044564
- Testing
- Bay 59-8862
- Where
- 29 sites in United States, Canada and 4 more
- Volunteers
- 54 people
- Sponsor
- Bayer
Carcinoma, Ovarian Cancer
A Phase 1 Study of the Safety and Pharmacokinetics of AGS-8M4 in Subjects With Advanced Ovarian Cancer
This is the first in human study of AGS-8M4 given every 2 weeks to subjects with advanced ovarian cancer. AGS-8M4 will be administered as an IV infusion until the disease worsens.
- Conditions
- Carcinoma, Ovarian Cancer, Ovarian Diseases, Ovarian Neoplasms
- Trial name
- NCT00816764
- Testing
- AGS-8M4
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Astellas Pharma Inc
HIV Infections, Gonorrhea
Trial to Evaluate PRO 2000/5 Gels for the Prevention of Vaginally Acquired HIV Infection
The objective of the study is to determine the efficacy and safety of 0.5% and 2% PRO 2000/5 gels compared to placebo in preventing vaginally acquired HIV infection.
- Conditions
- HIV Infections, Gonorrhea, Chlamydial Infections, Genital Herpes
- Trial name
- NCT00262106
- Testing
- PRO 2000/5
- Where
- 6 sites in South Africa, Tanzania and 2 more
- Volunteers
- 9,404 people, healthy volunteers welcome
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Bacterial Vaginosis
A Phase 2 Study of SYM-1219 to Treat Bacterial Vaginosis
The purpose of this research study is to test the safety and effectiveness of the oral investigational new drug, SYM-1219, for the treatment of bacterial vaginosis.
- Trial name
- NCT02147899
- Testing
- SYM-1219
- Where
- 16 sites in United States
- Volunteers
- 215 people
- Sponsor
- Symbiomix Therapeutics
Overactive Bladder
A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo
A new drug for overactive bladder is compared to placebo to determine if it is safe and effective. The study lasts approximately 12 weeks.
- Trial name
- NCT00350636
- Testing
- Oxybutynin topical gel
- Where
- 63 sites in United States
- Volunteers
- 789 people
- Sponsor
- Watson Pharmaceuticals
Hepatorenal Syndrome, Acute Kidney Injury
Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome
This study aims to evaluate the safety, tolerability and efficacy of R2R01 combined with terlipressin as compared to terlipressin alone in the treatment of patients with HRS-AKI
- Trial name
- NCT05875948
- Testing
- R2R01, Terlipressin
- Where
- 7 sites in United States
- Volunteers
- 95 people
- Sponsor
- River 2 Renal Corp.
Carcinoma, Renal Cell
Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma
To investigate safety and efficacy of single agent sunitinib malate as first-line systemic therapy in Chinese patients with metastatic renal cell carcinoma.
- Trial name
- MRCC RCC (NCT00706706)
- Testing
- Sunitinib Malate (SU011248)
- Where
- 11 sites in China
- Volunteers
- 105 people
- Sponsor
- Pfizer
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101
Subjects who received tesevatinib in Study KD019-101 and completed 24 months of treatment will continue on the dose of tesevatinib they were receiving at 24 months on the KD019-101 study.
- Trial name
- NCT02616055
- Testing
- tesevatinib
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- Kadmon Corporation, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.